Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | Are CAR T-cells worth the money in lymphoma?

Anna Sureda • 20 Jun 2019
ICML 2019
Lymphoma Non-Hodgkin Lymphoma CAR-T

Are CAR T-cells worth the money in lymphoma? Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses this important question at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Anna Sureda

Ask the Expert: Anna Sureda answers your lymphoma questions at EHA 2025
8:15
Ask the Expert: Anna Sureda answers your lymphoma questions at EHA 2025
Anna Sureda • 14 Jun 2025
The potential of Glofit-GemOx as a new standard of care in R/R DLBCL
1:32
The potential of Glofit-GemOx as a new standard of care in R/R DLBCL
Anna Sureda • 31 Mar 2025
Optimizing bridging therapy strategies before CAR T-cell therapy
2:10
Optimizing bridging therapy strategies before CAR T-cell therapy
Anna Sureda • 31 Mar 2025
EBV+ PTLD: clinical perspectives & insights into EBV-driven cell therapy
2:01
EBV+ PTLD: clinical perspectives & insights into EBV-driven cell therapy
Anna Sureda • 31 Mar 2025

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Anna Sureda • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Anna Sureda • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Anna Sureda • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Anna Sureda • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals